{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:09:43Z","timestamp":1780697383193,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ymgmr.2021.100718","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T22:40:43Z","timestamp":1612564843000},"page":"100718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["\u201cReal world effectiveness of cerliponase alfa in classical and atypical patients. A case series\u201d"],"prefix":"10.1016","volume":"27","author":[{"given":"O.M.","family":"Espitia Segura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.I.","family":"Mancilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Naranjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tavera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ymgmr.2021.100718_bb0005","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbamcr.2008.11.004","article-title":"Neuronal ceroid lipofuscinoses","volume":"1793","author":"Jalanko","year":"2009","journal-title":"Biochim Biophys Acta - Mol Cell Res [internet]"},{"issue":"5333","key":"10.1016\/j.ymgmr.2021.100718_bb0015","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1126\/science.277.5333.1802","article-title":"Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis","volume":"277","author":"Sleat","year":"1997","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ymgmr.2021.100718_bb0020","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/humu.23860","article-title":"Mutation update: review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease","volume":"40","author":"Gardner","year":"2019","journal-title":"Hum Mutat [internet]"},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100718_bb0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-0004.2008.01054.x","article-title":"The clinical and genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland","volume":"74","author":"Moore","year":"2008","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgmr.2021.100718_bb0030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","article-title":"Management strategies for CLN2 disease","volume":"69","author":"Williams","year":"2017","journal-title":"Pediatr. Neurol."},{"issue":"10","key":"10.1016\/j.ymgmr.2021.100718_bb0035","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.bbadis.2015.05.003","article-title":"The neuronal ceroid lipofuscinoses program: a translational research experience in Argentina","volume":"1852","author":"Kohan","year":"2015","journal-title":"Biochim Biophys Acta - Mol Basis Dis [internet]"},{"issue":"10","key":"10.1016\/j.ymgmr.2021.100718_bb0040","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbadis.2006.07.001","article-title":"Diagnosis of the neuronal ceroid lipofuscinoses: an update","volume":"1762","author":"Williams","year":"2006","journal-title":"Biochim Biophys Acta - Mol Basis Dis."},{"issue":"8","key":"10.1016\/j.ymgmr.2021.100718_bb0045","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","article-title":"Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study","volume":"2","author":"Nickel","year":"2018","journal-title":"Lancet Child Adolesc Heal."},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100718_bb0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00401-008-0349-3","article-title":"Atypical CLN2 with later onset and prolonged course: a neuropathologic study showing different sensitivity of neuronal subpopulations to TPP1 deficiency","volume":"116","author":"Elleder","year":"2008","journal-title":"Acta Neuropathol."},{"issue":"1\u20132","key":"10.1016\/j.ymgmr.2021.100718_bb0055","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ymgme.2016.07.011","article-title":"Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): expert recommendations for early detection and laboratory diagnosis","volume":"119","author":"Fietz","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100718_bb0060","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ddrr.1118","article-title":"The neuronal ceroid-lipofuscinoses","volume":"17","author":"Bennett","year":"2013","journal-title":"Dev Disabil Res Rev."},{"issue":"8","key":"10.1016\/j.ymgmr.2021.100718_bb0065","doi-asserted-by":"crossref","first-page":"e73128","DOI":"10.1371\/journal.pone.0073128","article-title":"Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function","volume":"8","author":"Orlin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2021.100718_bb0070","series-title":"The neuronal ceroid lipofuscinosis (Batten Disease). En: Mole, S. E. y R. E. G. H. Williams, editor. CLN2","first-page":"80","author":"Chang","year":"2011"},{"issue":"4","key":"10.1016\/j.ymgmr.2021.100718_bb0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ajmg.10660","article-title":"Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations","volume":"112","author":"Steinfeld","year":"2002","journal-title":"Am. J. Med. Genet."},{"issue":"6","key":"10.1016\/j.ymgmr.2021.100718_bb0080","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/01.wnl.0000267885.47092.40","article-title":"Neurological deterioration in late infantile neuronal ceroid lipofuscinosis","volume":"69","author":"Worgall","year":"2007","journal-title":"Neurology."},{"key":"10.1016\/j.ymgmr.2021.100718_bb0085","doi-asserted-by":"crossref","DOI":"10.1177\/2326409818788382","article-title":"An adapted clinical measurement tool for the key symptoms of CLN2 disease","volume":"6","author":"Wyrwich","year":"2018","journal-title":"J Inborn Errors Metab Screen."},{"issue":"20","key":"10.1016\/j.ymgmr.2021.100718_bb0090","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2021.100718_bb0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/TCRM.S241048","article-title":"Changing times for CLN2 disease: the era of enzyme replacement therapy","volume":"16","author":"Specchio","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ymgmr.2021.100718_bb0100","series-title":"Ministerio de Salud y de Protecci\u00f3n Social, Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA). Resoluci\u00f3n No. 201942117 de 24 de Septiembre de","year":"2019"},{"key":"10.1016\/j.ymgmr.2021.100718_bb0105","series-title":"\u00c9tica M\u00e9dica","first-page":"2","article-title":"C\u00f3digo de N\u00faremberg","volume":"1","author":"Mainetti","year":"1947"},{"key":"10.1016\/j.ymgmr.2021.100718_bb0110","series-title":"Declaraci\u00f3n Universal de los Derechos Humanos. Mineduc.cl [Internet]","first-page":"6","author":"Organizaci\u00f3n de las Naciones Unidas para la Educaci\u00f3n la Ciencia y la Cultura Unesco","year":"1948"},{"key":"10.1016\/j.ymgmr.2021.100718_bb0115","first-page":"1","article-title":"Ministerio de Salud y Protecci\u00f3n Social","volume":"1993","author":"Ministerio de Salud. Resoluci\u00f3n 8430 de","year":"1993","journal-title":"Rep\u00fablica de Colombia"},{"key":"10.1016\/j.ymgmr.2021.100718_bb0120","series-title":"En: International Encyclopedia of Ethics [Internet]","article-title":"Declaration of Helsinki","author":"Holm","year":"2013"},{"key":"10.1016\/j.ymgmr.2021.100718_bb0125","author":"National Center for Biotechnology Information"},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100718_bb0130","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ymgme.2007.08.124","article-title":"CLN2\/TPP1 deficiency: the novel mutation IVS7-10A>G causes intron retention and is associated with a mild disease phenotype","volume":"93","author":"Bessa","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100718_bb0135","first-page":"1","article-title":"Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: Insights from the largest cohort in the world","author":"Louren\u00e7o","year":"2020","journal-title":"J Paediatr Child Health"},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100718_bb0140","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.gene.2012.12.058","article-title":"Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America","volume":"516","author":"Kohan","year":"2013","journal-title":"Gene."},{"issue":"S38","key":"10.1016\/j.ymgmr.2021.100718_bb0145","article-title":"Late language acquisition and unexplaied epilepsy are indicators of easily detectable CLN2 disease","volume":"19","author":"Nickel","year":"2015","journal-title":"Eur J Paediatr Neurol."},{"key":"10.1016\/j.ymgmr.2021.100718_bb0150","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/01.wnl.0000267885.47092.40","article-title":"Neurological deterioration in late infantile neuronal ceroid lipofuscinosis","volume":"69","author":"Worgall","year":"2007","journal-title":"Neurology."},{"key":"10.1016\/j.ymgmr.2021.100718_bb0155","author":"Biomarin Pharmaceutical (Canada) Inc"},{"key":"10.1016\/j.ymgmr.2021.100718_bb0160","first-page":"2020","article-title":"Persistent Treatment Effect of Cerliponase Alfa in Children with CLN2 Disease: A 3 Year Update from an Ongoing Multicenter Extension Study","volume":"50","author":"Schulz","year":"2019","journal-title":"Abstr 45th Annu Meet Soc Neuropediatr"},{"key":"10.1016\/j.ymgmr.2021.100718_bb0165","article-title":"Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series","author":"Wibbeler","year":"2020","journal-title":"J Child Neurol."},{"key":"10.1016\/j.ymgmr.2021.100718_bb0170","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejpn.2020.12.002","article-title":"Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: the first French cohort","volume":"30","author":"Estublier","year":"2021","journal-title":"Eur J Paediatr Neurol [Internet]."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921000124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921000124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:51:59Z","timestamp":1762001519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426921000124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":33,"alternative-id":["S2214426921000124"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100718","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cReal world effectiveness of cerliponase alfa in classical and atypical patients. A case series\u201d","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100718"}}